IXJ vs XLV

Key Takeaways

• IXJ provides diversified global healthcare exposure across 114 holdings, including significant non-US names like Roche and AstraZeneca, contrasting XLV's concentrated US large-cap focus with 60 holdings from the S&P 500 healthcare sector.
• XLV offers superior cost efficiency with a 0.08% expense ratio versus IXJ's 0.40%, making it more attractive for long-term holding on a pure cost basis.
• Both ETFs exhibit low volatility profiles typical of healthcare, but IXJ's international diversification may provide a slight edge in relative stability during US-specific market rotations.
• XLV demonstrates markedly higher liquidity, with average daily volumes exceeding 10 million shares and tighter bid-ask spreads (0.01%), compared to IXJ's approximately 100,000 shares daily.
• Top holdings overlap substantially (e.g., LLY and JNJ), but IXJ allocates more to pharmaceuticals with global reach, while XLV emphasizes US providers like UNH.
• In recent market cycles, both have shown resilience amid sector headwinds, with IXJ slightly outperforming on a year-to-date basis due to international momentum.

Introduction

IXJ and XLV represent compelling options for investors seeking defensive sector exposure in healthcare, a resilient industry driven by aging demographics and innovation. While both target healthcare equities, they diverge structurally: IXJ delivers broad global coverage, capturing multinational pharmaceuticals and biotech leaders, whereas XLV focuses exclusively on large-cap US firms from the S&P 500 Health Care Select Sector Index. This comparison is particularly relevant amid recent capital rotations into defensives, policy shifts easing drug pricing pressures, and macroeconomic uncertainty favoring low-volatility assets. Investors weighing international diversification against US-centric liquidity and cost efficiency will find these ETFs as strategic alternatives for portfolio positioning in the current environment.

iShares Global Healthcare ETF (IXJ) Overview

The iShares Global Healthcare ETF (IXJ) is a passive ETF that seeks to track the S&P Global 1200 Health Care Index (transitioning to the S&P Global 1200 Health Care (Sector) Capped Index in early 2026). It provides exposure to global equities in the healthcare sector, including pharmaceuticals, biotechnology, and medical devices. With approximately $3.6 billion in assets under management (AUM), IXJ holds 114 securities, offering robust diversification.

Top holdings include LLY (9.96%), JNJ (7.07%), ABBV (4.72%), UNH (4.67%), and Roche Holding (3.87%), blending US giants with European leaders like AstraZeneca and Novartis. Sector allocations emphasize Pharma, Biotech & Life Sciences (68.90%) and Health Care Equipment & Services (30.43%). The expense ratio is 0.40%, and it exhibits solid liquidity with a 30-day average daily volume of about 95,000 shares and a median bid-ask spread of 0.13%. IXJ's global mandate distinguishes it for investors pursuing worldwide healthcare trends without currency hedging.

State Street Health Care Select Sector SPDR Fund (XLV) Overview

The State Street Health Care Select Sector SPDR Fund (XLV) is a passive ETF tracking the Health Care Select Sector Index, comprising large-cap US healthcare companies from the S&P 500. Managing over $37 billion in AUM, XLV holds 60 securities, delivering concentrated exposure to pharmaceuticals, providers, biotech, and equipment makers.

Leading positions feature LLY (14.47%), JNJ (10.27%), ABBV (6.86%), UNH (6.63%), and MRK (5.32%). Allocations break down as Pharmaceuticals (36.21%), Health Care Providers & Services (19.20%), Biotechnology (18.19%), and Health Care Equipment & Supplies (17.15%). Its ultra-low expense ratio of 0.08% enhances cost efficiency, while exceptional liquidity shines through with daily volumes often surpassing 10 million shares and a 0.01% median bid-ask spread. XLV suits those prioritizing US market dominance and minimal fees.

Industry and Thematic Backdrop

The healthcare sector operates in a supportive yet challenged environment, buoyed by aging populations, rising chronic disease prevalence, and breakthroughs in AI-driven drug discovery and precision medicine. Recent ETF inflows hit five-year highs in late 2025 at $6.8 billion, reflecting renewed confidence post-policy clarity on drug pricing like the One Big Beautiful Bill Act (OBBBA). Macro tailwinds include cooling inflation and steady consumer spending, though elevated interest rates and geopolitical tensions pose risks to capital costs.

Regulatory scrutiny persists on pricing and approvals, with ACA subsidy expirations potentially impacting enrollment. Capital flows favor defensives amid volatility, while sector risks encompass workforce shortages, supply chain pressures, and patent cliffs. Both ETFs benefit from these dynamics, with global innovation pipelines and US provider resilience as key catalysts in recent market cycles.

Performance and Positioning Comparison

In recent months, both IXJ and XLV have navigated healthcare headwinds, posting year-to-date declines around 6%, with IXJ showing marginal outperformance (-5.95% vs. XLV's -6.93%). This relative strength for IXJ stems from international holdings buoyed by ex-US pharma momentum, amid US sector rotation away from mega-caps.

Over broader cycles, healthcare's low beta (around 0.6) underscores defensive appeal, with volatility metrics closely matched (IXJ ~4.3% monthly, XLV ~4.1%). XLV's concentration amplifies gains from top holdings like LLY during earnings beats, while IXJ's diversification tempers drawdowns in US policy-sensitive periods. Positioning favors both amid interest rate stabilization and biotech revival, though XLV edges in liquidity-driven efficiency.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore the AI Screener today to uncover hidden gems in sectors like healthcare.

Tickeron AI Verdict

Tickeron’s AI currently favors XLV with moderate conviction (65% probability of relative outperformance over the next cycle). This preference rests on XLV's superior cost structure, massive scale for liquidity, and concentrated exposure to high-momentum US large-caps amid domestic sector recovery. While IXJ's global diversification enhances risk-adjusted profiles in volatile regimes, XLV's efficiency and alignment with capital flows position it as the structural frontrunner absent major international catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations